Fuente: WIPO "tobacco agriculture" The invention discloses a sweroside pharmaceutical preparation and application thereof in prevention of a tobacco mosaic virus. The sweroside pharmaceutical preparation comprises 0.1-99% of sweroside and the balance pharmaceutic adjuvant and/excipient which is/are acceptable in pharmacology. The sweroside used in the sweroside pharmaceutical preparation can be separated and prepared from swertia cincta burk, the method is simple and the extraction rate is high. The sweroside pharmaceutical preparation has wide application prospects in prevention of the tobacco mosaic virus. The sweroside is separated and obtained from the swertia cincta burk through a modern separation technology. An experiment shows that the sweroside can significantly inhibit the tobacco mosaic virus (TMV) infection activity and serves as a novel plant virus resistance activity ingredient to be used for preventing a TMV disease, and the inhibition effect of the sweroside pharmaceutical preparation is better than that of other sold TMV resistant plant preparations (such as ningnanmycin). The sweroside pharmaceutical preparation is a pure biological agent, is harmless to people and animals, has a significant effect on TMV disease prevention and can be used in production of organic tobaccos.